These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 16096006)
1. Targeted delivery of therapeutic oligonucleotides to pulmonary circulation. Wilson A; He F; Li J; Ma Z; Pitt B; Li S Adv Genet; 2005; 54():21-41. PubMed ID: 16096006 [TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Wilson A; Zhou W; Champion HC; Alber S; Tang ZL; Kennel S; Watkins S; Huang L; Pitt B; Li S Mol Ther; 2005 Sep; 12(3):510-8. PubMed ID: 15953766 [TBL] [Abstract][Full Text] [Related]
3. Cellular delivery of peptide nucleic acid by cell-penetrating peptides. Kilk K; Langel U Methods Mol Biol; 2005; 298():131-41. PubMed ID: 16044544 [TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells. Yang L; Li J; Zhou W; Yuan X; Li S J Control Release; 2004 Mar; 95(2):321-31. PubMed ID: 14980780 [TBL] [Abstract][Full Text] [Related]
5. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Wilson KD; de Jong SD; Tam YK Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375 [TBL] [Abstract][Full Text] [Related]
7. Addressing the challenges of cellular delivery and bioavailability of peptide nucleic acids (PNA). Nielsen PE Q Rev Biophys; 2005 Nov; 38(4):345-50. PubMed ID: 16600055 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Parekh HS; Marano RJ; Rakoczy EP; Blanchfield J; Toth I Bioorg Med Chem; 2006 Jul; 14(14):4775-80. PubMed ID: 16603365 [TBL] [Abstract][Full Text] [Related]
9. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111 [TBL] [Abstract][Full Text] [Related]
10. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177 [TBL] [Abstract][Full Text] [Related]
11. Imaging gene expression using oligonucleotides and peptide nucleic acids. Paroo Z; Corey DR J Cell Biochem; 2003 Oct; 90(3):437-42. PubMed ID: 14523977 [TBL] [Abstract][Full Text] [Related]
12. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Morris MC; Gros E; Aldrian-Herrada G; Choob M; Archdeacon J; Heitz F; Divita G Nucleic Acids Res; 2007; 35(7):e49. PubMed ID: 17341467 [TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation. Kuruba R; Wilson A; Gao X; Li S AAPS J; 2009 Mar; 11(1):23-30. PubMed ID: 19132538 [TBL] [Abstract][Full Text] [Related]
14. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides. Kim SH; Kim EJ; Hou JH; Kim JM; Choi HG; Shim CK; Oh YK Biomaterials; 2009 Feb; 30(5):959-67. PubMed ID: 19027156 [TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Li SD; Huang L Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857 [TBL] [Abstract][Full Text] [Related]
16. Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. Ma Z; Zhang J; Alber S; Dileo J; Negishi Y; Stolz D; Watkins S; Huang L; Pitt B; Li S Am J Respir Cell Mol Biol; 2002 Aug; 27(2):151-9. PubMed ID: 12151306 [TBL] [Abstract][Full Text] [Related]
17. Mitochondrial drug delivery and mitochondrial disease therapy--an approach to liposome-based delivery targeted to mitochondria. Yamada Y; Akita H; Kogure K; Kamiya H; Harashima H Mitochondrion; 2007; 7(1-2):63-71. PubMed ID: 17296332 [TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model. Kootiratrakarn T; Fujimura T; Sano K; Okuyama R; Aiba S; Tagami H; Terui T Eur J Immunol; 2005 Nov; 35(11):3277-86. PubMed ID: 16245360 [TBL] [Abstract][Full Text] [Related]